ANDA 216266, held by Prinston Pharmaceutical. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 216266 (Lisdexamfetamine Dimesylate), held by Prinston Pharmaceutical, was first approved by FDA on Aug 25, 2023, with 3 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate10MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 10, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 10, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 4, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters